NO20033622L - Fremgangsmate for behandling av demyeliniserende sykdommer eller tilstander - Google Patents

Fremgangsmate for behandling av demyeliniserende sykdommer eller tilstander

Info

Publication number
NO20033622L
NO20033622L NO20033622A NO20033622A NO20033622L NO 20033622 L NO20033622 L NO 20033622L NO 20033622 A NO20033622 A NO 20033622A NO 20033622 A NO20033622 A NO 20033622A NO 20033622 L NO20033622 L NO 20033622L
Authority
NO
Norway
Prior art keywords
treatment
conditions
demyelinating diseases
demyelinating
diseases
Prior art date
Application number
NO20033622A
Other languages
English (en)
Other versions
NO20033622D0 (no
Inventor
Craig Paul Smith
Michel P Rathbone
Margaret Petty
David Rampe
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NO20033622D0 publication Critical patent/NO20033622D0/no
Publication of NO20033622L publication Critical patent/NO20033622L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
NO20033622A 2001-02-15 2003-08-14 Fremgangsmate for behandling av demyeliniserende sykdommer eller tilstander NO20033622L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26884601P 2001-02-15 2001-02-15
GBGB0119435.6A GB0119435D0 (en) 2001-02-15 2001-08-09 Method of treating of demyelinating diseases or conditions
PCT/US2002/005501 WO2002064126A2 (en) 2001-02-15 2002-02-14 Method of treating of demyelinating diseases or conditions

Publications (2)

Publication Number Publication Date
NO20033622D0 NO20033622D0 (no) 2003-08-14
NO20033622L true NO20033622L (no) 2003-10-06

Family

ID=23024747

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033622A NO20033622L (no) 2001-02-15 2003-08-14 Fremgangsmate for behandling av demyeliniserende sykdommer eller tilstander

Country Status (39)

Country Link
US (10) US6967210B2 (no)
EP (1) EP1368031A2 (no)
JP (3) JP2004518711A (no)
KR (3) KR100951542B1 (no)
CN (2) CN1529598A (no)
AP (1) AP1749A (no)
AR (1) AR035750A1 (no)
AU (3) AU2002247200B9 (no)
BR (1) BR0207272A (no)
CA (1) CA2438712A1 (no)
CO (1) CO5390085A1 (no)
CR (1) CR7023A (no)
CZ (1) CZ20032172A3 (no)
EA (2) EA011319B1 (no)
EC (1) ECSP024218A (no)
EE (1) EE200300363A (no)
GB (1) GB0119435D0 (no)
HK (1) HK1080361B (no)
HR (1) HRP20030652A2 (no)
HU (1) HUP0303203A3 (no)
IL (2) IL157341A0 (no)
MA (1) MA26152A1 (no)
ME (1) MEP21208A (no)
MX (1) MXPA03006110A (no)
MY (1) MY157745A (no)
NO (1) NO20033622L (no)
NZ (4) NZ527011A (no)
OA (1) OA12549A (no)
PA (1) PA8540101A1 (no)
PE (1) PE20040175A1 (no)
PL (1) PL363638A1 (no)
SG (1) SG134170A1 (no)
SK (1) SK10392003A3 (no)
TR (4) TR200800693T2 (no)
TW (1) TWI325319B (no)
UA (2) UA80394C2 (no)
WO (1) WO2002064126A2 (no)
YU (1) YU62903A (no)
ZA (1) ZA200306124B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
AU2003301184A1 (en) * 2002-12-20 2004-07-22 Dynogen Pharmaceuticals Inc METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING Alpha2Delta SUBUNIT CALCIUM CHANNEL MODULATORS
WO2004066990A2 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
BRPI0408608A (pt) * 2003-03-21 2006-03-07 Dynogen Pharmaceuticals Inc uso de moduladores da subunidade (alfa)2(delta) de canal de cálcio e moduladores de músculo liso para tratamento de sintoma de um distúrbio do trato urinário inferior
GT200500063A (es) * 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
GB0510164D0 (en) * 2005-04-28 2005-06-22 Paradigm Therapeutics Ltd Ion channel
FR2892021B1 (fr) * 2005-10-19 2008-01-04 Urogene Traitement de l'incontinence urinaire d'effort et mixte
FR2892022B1 (fr) * 2005-10-19 2008-01-04 Urogene Sa Traitement des symptomes de l'irritation de la vessie
US8420593B1 (en) * 2006-06-16 2013-04-16 Landon C. G. Miller Compositions and methods for regulating membrane potential
DE102008044844B4 (de) * 2008-08-28 2018-08-30 Siemens Healthcare Gmbh Verfahren zur Ermittlung einer Schwächungskarte zur Verwendung in der Positronenemissionstomographie und von Homogenitätsinformationen des Magnetresonanzmagnetfeldes
KR101862539B1 (ko) * 2010-03-26 2018-05-31 가부시키가이샤 한도오따이 에네루기 켄큐쇼 반도체 장치
WO2012009204A1 (en) * 2010-07-15 2012-01-19 The Trustees Of Columbia University In The City Of New York Methods for diagnosing and treating concussive disorders
US20130030025A1 (en) * 2011-01-28 2013-01-31 Wessel Thomas C Use of potassium channel blockers to treat cerebral palsy
TWI592156B (zh) * 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
EP3727587A4 (en) 2017-12-22 2022-02-23 Massachusetts Institute Of Technology COMPOSITIONS AND METHODS FOR THERAPY OF WILLIAMS SYNDROME (WS)
EP4281118A1 (en) * 2021-01-20 2023-11-29 Rush University Medical Center Improved treatment for globoid cell leukodsytrophy or krabbe disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970218A (en) * 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
US4880822A (en) * 1987-04-24 1989-11-14 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyridinyl)-1H-indol-1-amines
EP0287982B1 (en) * 1987-04-24 1994-12-07 Hoechst-Roussel Pharmaceuticals Incorporated N-(Pyridinyl)-1H-indol-1-amines, a process for their preparation and their use as medicaments
EP0415103B1 (en) * 1989-08-02 1995-02-01 Hoechst-Roussel Pharmaceuticals Incorporated 2,3-Dihydro-1-(pyridinylamino)-indoles, a process for their preparation and their use as medicaments
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
US5459274A (en) * 1994-05-13 1995-10-17 Hoechst-Roussel Pharmaceuticals Inc. Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
EP0731108A1 (en) * 1995-03-10 1996-09-11 Boehringer Mannheim Gmbh Method of manufacturing a therapeutic agent for the regeneration of oligodendrocytes
FR2754147B1 (fr) 1996-10-03 2000-02-04 Mbh Technologies Sa Installation et procede pour le traitement de carcasses
DE69912250T2 (de) * 1998-01-29 2004-07-29 Bristol-Myers Squibb Co., Wallingford Phosphorylierte derivate des diaryl 1,3,4 oxadiazolon
WO2001004091A1 (en) * 1999-07-09 2001-01-18 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions

Also Published As

Publication number Publication date
US7230015B2 (en) 2007-06-12
NZ527011A (en) 2005-07-29
EP1368031A2 (en) 2003-12-10
WO2002064126A2 (en) 2002-08-22
KR20090005254A (ko) 2009-01-12
HRP20030652A2 (en) 2005-06-30
UA88773C2 (ru) 2009-11-25
KR100951540B1 (ko) 2010-04-09
PE20040175A1 (es) 2004-03-29
MA26152A1 (fr) 2004-07-01
IL157341A (en) 2010-11-30
US6967210B2 (en) 2005-11-22
HK1080361B (zh) 2009-10-30
CN100522164C (zh) 2009-08-05
GB0119435D0 (en) 2001-10-03
EE200300363A (et) 2003-10-15
KR20090005255A (ko) 2009-01-12
CN1529598A (zh) 2004-09-15
AU2002247200B2 (en) 2007-12-13
CO5390085A1 (es) 2004-04-30
TR200800693T2 (tr) 2008-07-21
AU2008201179A1 (en) 2008-04-03
AP1749A (en) 2007-06-13
MEP21208A (en) 2010-06-10
ECSP024218A (es) 2003-09-24
NZ539159A (en) 2006-11-30
AU2008201179B2 (en) 2009-08-20
US20090209594A1 (en) 2009-08-20
US20090281147A1 (en) 2009-11-12
NZ556697A (en) 2009-01-31
AU2009238332A1 (en) 2009-12-10
CZ20032172A3 (cs) 2004-01-14
JP2009185045A (ja) 2009-08-20
EA011319B1 (ru) 2009-02-27
MXPA03006110A (es) 2005-07-01
TR200301330T2 (tr) 2004-12-21
CN1679564A (zh) 2005-10-12
MY157745A (en) 2016-07-15
TR200800692T2 (tr) 2008-03-21
CR7023A (es) 2003-11-17
HK1080361A1 (en) 2006-04-28
IL157341A0 (en) 2004-02-19
US20040157889A1 (en) 2004-08-12
NZ544720A (en) 2007-08-31
US20040157888A1 (en) 2004-08-12
OA12549A (en) 2006-06-05
US7534803B2 (en) 2009-05-19
SG134170A1 (en) 2007-08-29
US20050234105A1 (en) 2005-10-20
JP2010120958A (ja) 2010-06-03
AR035750A1 (es) 2004-07-07
NO20033622D0 (no) 2003-08-14
PA8540101A1 (es) 2003-09-05
ZA200306124B (en) 2004-11-08
EA200600896A1 (ru) 2006-08-25
US20030105150A1 (en) 2003-06-05
US7179821B2 (en) 2007-02-20
KR20040014459A (ko) 2004-02-14
BR0207272A (pt) 2004-02-10
JP2004518711A (ja) 2004-06-24
AP2003002834A0 (en) 2003-09-30
US20050159456A1 (en) 2005-07-21
CA2438712A1 (en) 2002-08-22
HUP0303203A2 (hu) 2003-12-29
YU62903A (sh) 2006-05-25
EA200300882A1 (ru) 2003-12-25
US20090209595A1 (en) 2009-08-20
WO2002064126A3 (en) 2003-02-20
US20060025452A1 (en) 2006-02-02
UA80394C2 (en) 2007-09-25
TR200800691T2 (tr) 2008-03-21
EA012409B1 (ru) 2009-10-30
KR100951542B1 (ko) 2010-04-09
PL363638A1 (en) 2004-11-29
HUP0303203A3 (en) 2007-11-28
US20090270458A1 (en) 2009-10-29
AU2002247200B9 (en) 2008-07-10
SK10392003A3 (sk) 2004-01-08
TWI325319B (en) 2010-06-01

Similar Documents

Publication Publication Date Title
NO20033594D0 (no) Fenetanolamin-derivater for behandling av luftveissykdommer
DE60202169D1 (de) Verfahren zur Herstellung von Flockungsmittel zur Wasserbehandlung
DE60230425D1 (de) Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
NO20033622L (no) Fremgangsmate for behandling av demyeliniserende sykdommer eller tilstander
DE60222644D1 (de) Prozess zur herstellung von transparenten formteilen
DE50201891D1 (de) Verfahren zur herstellung von 1-octen
DE60223070D1 (de) Verfahren zur herstellung von dihalogenadamantanen
DE60218451D1 (de) 15-keto-prostaglandine zur behandlung arzneimittelinduzierter obstipation
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
NO20040278L (no) Fremgangsmate for fremstilling av perindopril
DE60208562D1 (de) Verfahren zur herstellung von tagatose
DE60219193D1 (de) Verfahren zur herstellung von silylorganomercaptanen
DE60208738D1 (de) Verfahren zur Herstellung von Chlorfluorpolyoxyalkylenolen
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
NO20044814L (no) Fremgangsmate for fremstilling av combretastaniner
FI20012170A (fi) Menetelmä lauhteiden käsittelemiseksi
NO20035538D0 (no) Fremgangsmåte for fremstilling av zaleplon
DE60233589D1 (de) Verfahren zur herstellung von echinocandinderivaten
NO20023445L (no) Fremgangsmåte for fremstilling av peptider
DE50210487D1 (de) Verfahren zur Herstellung von 1-Amino-4-hydroxyanthrachinonen
NO20035586L (no) Fremgangsmate for fremstilling av cykloheksanol-derivater
NO20020784D0 (no) Medikament for behandling av brudd
DE60209171D1 (de) Verfahren zur Herstellung von Bromfluorenen
NO20012612L (no) Isonipecotamider for behandlingen av integrin-formidlede sykdommer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application